Method for the Treatment of Depression and Anxiety

This technology relates to a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin. This modified version of SHU9119 can antagonize the Melanocortin 5 Receptor (MC5R), potentially enabling rapidly-acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders.

Background: 
Current treatments for depression include drugs with delayed therapeutic onset.  This technology has the potential to fill this unmet need with a therapy that is specific to MC5R for treating depression and other mood disorders.

Applications:

• Pharmaceutical compound for the treatment of depression, anxiety, and other mood disorders

Advantages:

• Targets specific receptor minimizes undesirable side effects
• May achieve therapeutic effect in less time than alternative pharmacological interventions

Status: issued U.S. patent #9,814,755